Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities

Kelly K. Curtis, Jonathan B. Ashman, Christopher P. Beauchamp, Adam J. Schwartz, Matthew D. Callister, Amylou Dueck, Leonard L. Gunderson, Tom R. Fitch

Research output: Contribution to journalArticle

20 Scopus citations


Background: Neoadjuvant chemoradiation (NCR) prior to resection of extremity soft tissue sarcoma (STS) has been studied, but data are limited. We present outcomes with NCR using a variety of chemotherapy regimens compared to neoadjuvant radiation without chemotherapy (NR) and surgery alone (SA).Methods: We conducted a retrospective chart review of 112 cases.Results: Treatments included SA (36 patients), NCR (39 patients), and NR (37 patients). NCR did not improve the rate of margin-negative resections over SA or NR. Loco-regional relapse-free survival, distant metastases-free survival, and overall survival (OS) were not different among the treatment groups. Patients with relapsed disease (OR 11.6; p = 0.01), and tumor size greater than 5 cm (OR 9.4; p = 0.01) were more likely to have a loco-regional recurrence on logistic regression analysis. Significantly increased OS was found among NCR-treated patients with tumors greater than 5 cm compared to SA (3 year OS 69 vs. 40%; p = 0.03). Wound complication rates were higher after NCR compared to SA (50 vs. 11%; p = 0.003) but not compared to NR (p = 0.36). Wet desquamation was the most common adverse event of NCR.Conclusions: NCR and NR are acceptable strategies for patients with STS. NCR is well-tolerated, but not clearly superior to NR.

Original languageEnglish (US)
Article number91
JournalRadiation Oncology
Issue number1
StatePublished - Aug 9 2011



  • Chemoradiation
  • Chemotherapy
  • Extremity
  • Neoadjuvant
  • Radiation
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this